Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third View: Investigating the results from the phase 2b FRONTIER clinical trial of JNJ-2113 in plaque psoriasis.

Ticker(s): JNJ

Who's the expert?

Institution: UC Irvine

Immunodermatologist and Professor of Dermatology at University of California Irvine Medical Center.
Treats 100 patients with Pemphigus, 100 patients with chronic itch, including 50 with Prurigo Nodularis, and 75 with alopecia areata.
Leading expert and researcher on autoimmune related skin conditions; has published more than 225 papers/book chapters and awarded numerous research grants from NIH.

Interview Goal

to discuss the current standard of care and the potential of JNJ-2113, an oral peptide being developed by Johnson & Johnson for the treatment of plaque psoriasis.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.